TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02059538

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual energy X-ray absorptiometry-scan (DEXA-scan)
Study: NCT01777009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Total Knee Replacement Surgery
Description: Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Total Knee Replacement Surgery
Description: Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
Study: NCT02398487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cigalike with nicotine
Description: cigalike 24 mg nicotine or 16 mg nicotine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Vaporizer with nicotine
Description: Personal Vaporizer 16 mg nicotine or 9 mg nicotine
Study: NCT02576275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
Study: NCT02903368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Study: NCT02576275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
Study: NCT02632071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACY-1215
Description: An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACY-1215
Description: An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACY-1215
Description: An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACY-1215
Description: An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
Study: NCT01231438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela
Description: 800mg t.i.d. over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etalpha
Description: 0.25ug o.d. for 2 weeks
Study: NCT03821636

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Roux-en-Y gastric bypass
Description: Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long alimentary limb Roux-en-Y gastric bypass
Description: Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
Study: NCT04664998

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic test for NG/CT
Description: All participants will receive diagnostic testing for NG/CT at each quarterly visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic test for NG/CT
Description: All participants will receive diagnostic testing for NG/CT at each quarterly visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: All participants will receive diagnostic testing for NG/CT at each quarterly visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: All participants will receive diagnostic testing for NG/CT at each quarterly visit.
Study: NCT02612142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: endurance-training or stretching (sham exercise)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: physical exercise
Description: endurance-training or stretching (sham exercise)
Study: NCT01746706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET amyloid tracer (Florbetapir F18 AV45 F18

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET amyloid tracer (Florbetapir F18 AV45 F18
Study: NCT01790672

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Vodka Absolut

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Lemon-flavored water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcoholized wine
Description: Wine 13º or wine 8º

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: De-alcoholized wine
Description: Wine 0º
Study: NCT05688540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e book
Description: e book

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional education booklet
Description: traditional education booklet
Study: NCT02280096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-aminopyridine
Description: Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm will include Microcrystalline Cellulose placebo
Study: NCT03169114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin Injection
Description: Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendicectomy
Description: Patients allocated to Surgery Management Strategy will undergo appendicectomy
Study: NCT00581126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor IX Coagulation
Description: Benefix IV each 12 hours for 2 a 5 days
Study: NCT00802594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB289
Description: A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
Study: NCT03936426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64 SARTATE and Cu-67 SARTATE
Description: Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
Study: NCT02005263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingography
Description: Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
Study: NCT04400682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVIRA 200 MG Film Tablet
Description: FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVIRA 200 MG Film Tablet
Description: FAVIRA is containing 200 mg favipiravir manufactured by Novelfarma, Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 MG Film Tablets
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 MG Film Tablets
Description: AVIGAN is containing 200 mg favipiravir manufactured by Toyama, Japan
Study: NCT03247192

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein-placebo
Description: This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo-whey protein
Description: This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-placebo
Description: This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
Study: NCT02445976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel: given orally once daily in 28-day cycles
Description: Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Study: NCT00570700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 150mg (3 pills) orally daily for as long as the drug benefits
Study: NCT03131128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: 1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Intervention
Description: 1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia.
Study: NCT01094626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin
Description: Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
Study: NCT03547102

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cherry concentrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo concentrate
Study: NCT03257410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Description: Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Study: NCT02733146

Intervention type: OTHER
Intervention: cardiac arrest
Study: NCT04106180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
Study: NCT03633513

Intervention type: DIAGNOSTIC_TEST
Intervention: LBT-3627
Description: Immunomodulatory agent

Intervention type: DIAGNOSTIC_TEST
Intervention: LBT-3627
Description: Immunomodulatory agent
Study: NCT02854631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Selonsertib placebo tablet administered orally once daily
Study: NCT04051008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online - use of online grocery shopping platform
Description: The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
Study: NCT03257410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-17H dialyzer
Description: Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Study: NCT03907306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound healing
Description: The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound healing
Description: The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
Study: NCT02624141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
Study: NCT01953692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03633513

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunological profiling
Description: Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunological profiling
Description: Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
Study: NCT02947334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab
Description: Bococizumab PFS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01953692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT01086449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK 1437173A
Description: Investigational vaccine (GSK 1437173A) administered intramuscularly.
Study: NCT02946151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNEEG implantable EEG electrode and data storage device
Description: The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
Study: NCT05639829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Restriction of calorie intake to an 8-hour window, with water only fasting in the remaining 16 hours of the 24-hour period
Study: NCT02611518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
Study: NCT01953692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 mg
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Description: oral capsule
Study: NCT00799552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10045
Description: RX-10045 eye drop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drop